Evidence map›Paper›PMID 17299483›Full record

ArticleEuropean journal of clinical nutrition2007

Consumption of an n-3 polyunsaturated fatty acid-enriched dip modulates plasma lipid profile in subjects with diabetes type II.

M L Garg, R J Blake, E Clayton, I A Munro, L Macdonald-Wicks, H Singh, P J Moughan

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical nutrition, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02349555 (An Open-Label Single-Center Study to Determine Safety and Effects of Novel Nutritional Blend on Inflammatory Balance Markers and Metabolic Parameters), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02349555 nacompletednot on this mapstarted 2015, after this paper: background citation

An Open-Label Single-Center Study to Determine Safety and Effects of Novel Nutritional Blend on Inflammatory Balance Markers and Metabolic Parameters

TypeinterventionalSponsorPharmanexRan2015 to 2016Enrolled41ConditionsOther Endocrine/Nutritional/Metabolic DisorderArmsNutritional Supplement Blend
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. (n-3) Fatty Acids: Clinical Trials in People with Type 2 Diabetes.Advances in nutrition (Bethesda, Md.) · 2010
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M L GargNutraceuticals Research Group, Faculty of Health, School of Biomedical Sciences, University of Newcastle, Callaghan, New South Wales, Australia. manohar.garg@newcastle.edu.au
R J Blake
E Clayton
I A Munro
L Macdonald-Wicks
H Singh
P J Moughan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRecent developments in micro-emulsification technology have allowed the fortification of foods with long-chain n-3 polyunsaturated fatty acid (PUFA) without the undesirable fish odour/taste and with reasonable shelf life. The effects of supplementing the diets of people with diabetes type II with a hummus-based dip enriched with long-chain n-3PUFA on plasma fatty acid composition and lipid levels were examined.

designA pre- and post-intervention study.

settingThis study was conducted at the University of Newcastle, Australia. SUBJECTS: Participants were recruited via advertisements on the University of Newcastle notice boards and in the local newspapers. Following initial response to study advertisements, information statements were mailed out to 29 potential participants. Thirteen participants were eligible and consented to participate in the trial. There were no dropouts as all the 13 participants completed 6-week intervention trial.

methodsFree-living male and female subjects with diabetes type II (n=13) consumed the n-3PUFA-enriched dip for a period of 6 weeks. Fasting blood samples were collected pre- and post-intervention for analyses of fatty acids and plasma lipids.

resultsFollowing 6 weeks of consuming the enriched dip, all the long-chain n-3PUFA (20:5n-3, 22:5n-3 and 22:6n-3) were significantly (P<0.05) elevated in the plasma lipids. This represented an increase in 20:5n-3 content by 117%, an increase in 22:5n-3 content by 15% and an increase in 22:6n-3 content by 80% over the baseline values before dip consumption. A significant reduction (P<0.05) in the plasma triglyceride levels from 1.93 (1.08-2.09) mmol/l at baseline to 1.27 (0.93-2.22) mmol/l after 6 weeks was also apparent following the consumption of the n-3PUFA-enriched dip. Plasma cholesterol was unchanged; however, low-density lipoprotein (LDL)-cholesterol (2.46+/-0.21 versus 2.72+/-0.22 mmol/l, P<0.034) and high-density lipoprotein (HDL)-cholesterol (1.16+/-0.09 versus 1.22+/-0.09 mmol/l, P<0.042) were significantly increased following the dietary intervention.

conclusionsThese results demonstrate that n-3PUFA are readily bioavailable from the fortified dip matrix and alter the plasma lipid profile.

Indexed as

Food, FortifiedAdultBiological AvailabilityCholesterolCholesterol, HDLCholesterol, LDLDiabetes Mellitus, Type 2Fatty Acids, Omega-3FemaleHumansIntestinal AbsorptionLipid MetabolismLipidsMaleTriglyceridesCholesterolCholesterol, HDLCholesterol, LDLFatty Acids, Omega-3LipidsTriglycerides

Identifiers

PMID17299483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.